“…Additionally, the inhibitory effects of BDMC33 were associated with the suppression of AP-1 DNA-binding activity by halting the JNK and ERK signalling pathways, as well as the inactivation of NF-ĸβ signalling, which occurred due to the attenuation of I-ĸB degradation, I-ĸB phosphorylation, NF-ĸβ translocation, and DNA binding [ 48 ]. In association with the present study, it is assumed that BDMC33 interacts with a noncanonical BMP signalling pathway that initiates upon the binding of TNBS to the TLR4 receptor and transduces a signal in association with MyD88, thereby activating IKK MAPK [ 51 ] and initiating cross talk with canonical members (Smad 1/5/8) of BMP signalling to inhibit downstream phosphorylation [ 15 ] and the nuclear translocation of I-ĸB, ERK/JNK, and the Smad1/5/8-Smad4 complex [ 52 ] and attenuate the upregulation of the BMP2a, BMP4, BMP6 and BMP7b genes. Overall, both the canonical and noncanonical pathways of BMP signalling are concerted in this process in which a protein kinase, MAPK, and a transcription factor, NF-κB, play a key role to suppress the inflammatory state of the BMP2a, BMP4, BMP6, and BMP7b genes.…”